Showing 5311-5320 of 9401 results for "".
- Bristol Myers Squibb: Positive Topline Results Pivotal Phase 3 Psoriasis Study of Deucravacitinibhttps://practicaldermatology.com/news/bristol-myers-squibb-positive-topline-results-pivotal-phase-3-psoriasis-study-of-deucravacitinib/2460678/Bristol Myers Squibb shared positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib, a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate to s
- Study: Aerolase Neo Elite Laser Is as Effective as the Gold Standard Laser for Treating Psoriasishttps://practicaldermatology.com/news/study-aerolase-neo-elite-laser-is-as-effective-as-the-gold-standard-laser-for-treating-psoriasis/2460674/The efficacy and tolerance of the 650-microsecond 1064-nm Nd:YAG laser (Aerolase NeoElite) is equivalent to the excimer laser for the treatment of mild to moderate psoriasis vulgaris of the arms and legs, according to a new study in the Journal of Drugs in Dermatology.
- People with Severe Atopic Dermatitis May Have Increased Risk of Death from Several Causeshttps://practicaldermatology.com/news/people-with-severe-atopic-dermatitis-may-have-increased-risk-of-death-from-several-causes/2460673/Although there is limited evidence for overall increased mortality in patients with atopic eczema, those with severe atopic eczema may have a greater risk of dying from several health issues compared with those without eczema, according to a new study in the Journal of Allergy and Clinical Im
- NRS Survey Finds Rosacea Patients Lack Knowledge of Antibiotic Resistancehttps://practicaldermatology.com/news/nrs-survey-finds-rosacea-patients-lack-knowledge-of-antibiotic-resistance/2460671/A majority of rosacea patients have never heard of antibiotic resistance, results of a recent survey by the National Rosacea Society (NRS) show. Yet topical or oral antibiotics are among the most commonly prescribed treatments for rosacea. The NRS’s rec
- Galderma's New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://practicaldermatology.com/news/galdermas-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2460668/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Pulse Biosciences Scores CE Mark for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-ce-mark-for-cellfx-system/2460666/Pulse Biosciences, Inc. received CE mark for the CellFXSystem. The Company can now proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU) for the treatment of general dermatologic conditions, including sebaceous hyperplasia (S
- Candela Launches Frax Pro Systemhttps://practicaldermatology.com/news/candela-launches-frax-pro-system/2460665/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD),
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not y
- Verrica: Post-Hoc Analyses Show Benefits of VP-102 at Specific Siteshttps://practicaldermatology.com/news/verrica-post-hoc-analyses-show-benefits-of-vp-102-at-specific-sites/2460661/Positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials demonstrate the safety and efficacy of Verrica Pharmaceuticals’ lead product candidate VP-102 in molluscum contagiosum (molluscum) in specific body regions. The data were presented in poster format online for the